Digbi Health Publishes Results Showing Precision Biology-Driven Lifestyle Care Delivers Clinically Superior IBS Relief

October 2, 2026 /Digbi News/ -- Members of Digbi Health's precision biology program, which personalizes nutrition, lifestyle, and clinical care to each person's gut microbiome, genetics, and continuous glucose response, saw their irritable bowel syndrome (IBS) symptom severity fall by an average of 48 points within 12 weeks. More than half of symptomatic members improved by at least 50 points, the threshold for a clinically meaningful change. The results, from a real-world analysis posted as a preprint on medRxiv.

Personalization at the root

Most IBS care starts with a list of foods to avoid and proceeds by trial and error. Digbi starts with biology, building each member's nutrition and lifestyle plan around their genes, gut microbiome, and glucose response, with clinicians and coaches guiding the change. Members with the most severe symptoms gained the most. Those whose meals became more nutrient-dense improved further, while weight loss was not associated with symptom change.

• 47.7-point average reduction in IBS Symptom Severity Scale score at 12 weeks
• 53.8% of symptomatic members improved by at least 50 points
• Benefit consistent across age, sex, body mass index, income, and ethnicity
• Results not explained by medication use or by starting a GLP-1 drug

A deeper read of the gut

Digbi has expanded its gut microbiome panel to read the genes of a member's gut bacteria and identify the species that produce inflammatory metabolites. These include bacterial dipeptidyl peptidase (DPP) enzymes, which break down GLP-1, the gut hormone that GLP-1 medicines mimic. The panel provides clinicians with a direct view of the chemistry underlying a member's symptoms and links GI care to Digbi's GLP-1 care.

One platform

Digbi unifies metabolic, GI, inflammatory, and hormonal care on a single, precision-biology platform. A member managing weight, glucose, gut symptoms, or menopause works with a single care team that can see all of their data, and employers and health plans contract for a single program rather than several.

IBS has been managed for decades with lists of foods to avoid and a lot of guesswork. Precision biology replaces the guesswork. When we read a person's genes, gut microbiome, and glucose response, we address what is actually driving their symptoms, and the relief holds up under the most conservative statistical tests.

— Ranjan Sinha, Founder and Chief Executive Officer, Digbi Health

The preprint, which has not yet been peer reviewed, is available on medRxiv.